Commercialized Products & Marketed Therapies

Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, headquartered in Indianapolis, Indiana and founded in 1876, best known for its diabetes, obesity and neuroscience medicines. Lilly entered the psychedelic field in July 2026 by agreeing to acquire AtaiBeckley for up to approximately US$3.8 billion (US$6.75 per share in upfront cash, about US$2.8 billion, plus up to US$2.50 per share in milestone-based contingent value rights). Expected to close in the third quarter of 2026, the deal brings Lilly a late-stage psychedelic and neuroplastogen pipeline led by BPL-003, an intranasal formulation of mebufotenin (5-MeO-DMT) in Phase 3 for treatment-resistant depression, alongside VLS-01 (a DMT oral film) and EMP-01 (an oral (R)-MDMA candidate). It is the largest psychedelic-focused acquisition to date, though Lilly notably avoided the term "psychedelic" in its announcement.

Canadian specialty pharmaceutical company focused on ketamine-based therapies for psychiatric and neurological conditions. KETARX™ (racemic ketamine IV) received FDA approval in August 2025, making PharmaTher one of the first Canadian companies to achieve US regulatory approval for a ketamine product. Also developing KETABET, a proprietary combination of ketamine and betaine.

Spirit Pharmacist provides psychedelic psychopharmacology education and consulting, including courses, webinars, drug-interaction guides, and pharmacist-led support for psychedelic and psychiatric medication questions.

The US subsidiary of Teva Pharmaceutical Industries, one of the world's largest pharmaceutical companies. Teva is known globally as a leader in generic medicines and also markets specialty branded drugs for neurological, respiratory, and oncology conditions, with headquarters in Israel and major operations worldwide.

A physician-founded, science-focused medical cannabis company operating cultivations, manufacturing facilities, and dispensaries across multiple US states. Vireo Health integrates medical expertise and pharmaceutical-grade production to provide cannabis-based treatments to patients, with operations in Maryland, Minnesota, and New York and a focus on evidence-based medicine and patient care.

An Australian biotech company developing proprietary synthetic psilocybin formulations and novel psychedelic therapies for mental health disorders. Woke Pharmaceuticals sponsors clinical trials for treatment-resistant depression partnering with leading universities including Swinburne University and the University of Western Australia, and is developing novel LSD analogues through research collaboration aimed at improving therapeutic profiles.